E20 Adaptive Designs for Clinical Trials
Introduction & Context In June 2025, the International Council for Harmonisation (ICH) released a draft guideline titled “Adaptive Designs for Clinical Trials (E20)”, currently under public consultation. U.S. Food and Drug Administration This draft, intended to harmonize global regulatory and scientific expectations, addresses the use of adaptive designs in confirmatory clinical trials (i.e., trials intended […]
A Deep Dive into the FDA Approval of NDA 215244 (s000): What We Know, What It Means, and What Comes Next
Introduction The issuance of label 215244s000 marks the formal U.S. FDA approval of a new therapeutic agent (or new indication) under NDA 215,244. While publicly available summaries are scarce, the full prescribing label document offers a wealth of technical information that can be unpacked to understand the drug’s mechanism, safety/efficacy profile, clinical trial evidence, potential […]
Understanding the FDA’s Key Developments on Drug Approvals and Public Health: A Deep Dive into the Latest FDA Release
Introduction: The U.S. Food and Drug Administration (FDA) plays a crucial role in safeguarding public health by regulating food, drugs, medical devices, and more. The FDA’s guidance and regulations are not only pivotal in ensuring safety but also in shaping the future of medical innovations and treatments. Recently, the FDA released a comprehensive document outlining […]
FDA Guidance on Medical Device Cybersecurity: A Crucial Step in Safeguarding Healthcare Technology
In an increasingly connected world, cybersecurity in healthcare technology has never been more critical. With medical devices becoming more integrated into hospital networks, clinical workflows, and patient care, their vulnerability to cyber threats has raised significant concerns. The FDA’s guidance on cybersecurity for medical devices offers essential guidelines to ensure the protection of these devices […]
Inside PRAC (Sept 2025): What EMA’s Safety Experts Decided, and What That Means for You
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) met from 1-4 September 2025. Their role: monitor the safety of medicines in the EU, assess risk signals, recommend actions, and ensure the benefit/risk of drugs remains favorable. Here are the key takeaways from the meeting, plus deeper insight into why they matter. Key Decisions & […]
When Sleep Therapy Devices Go Wrong: Philips DreamStation Ventilator Recall Explained
Sleep apnea affects millions. For many, devices like CPAPs or BiPAPs are lifelines — nightly helpers that keep airways open, ensure proper oxygenation, and protect against serious health risks. So when devices meant to heal can potentially misbehave, it’s a serious matter. Recently, Philips Respironics initiated a recall for certain DreamStation Auto CPAP / Auto […]
FDA’s Real-Time Adverse Event Reporting Dashboard for Cosmetics: A New Era of Transparency
Published: September 2025 Imagine you bought a new shampoo, hair dye, or moisturizer. A few days later, you notice a rash, excessive itching, or even worse. What would you do? Report it—but often, you might wonder whether your report ever makes a difference. With the FDA’s launch of its new dashboard for real-time adverse event […]
Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations Guidance for Industry
Understanding the Guidance: What, Why, How In September 2025, the U.S. Food and Drug Administration (FDA) issued a nonbinding guidance for industry titled “Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations.” U.S. Food and Drug Administration This document gives detailed recommendations for sponsors developing therapeutic protein biosimilars, especially how to design […]
FDA’s Guidance on Alternative Tools for Assessing Drug Manufacturing Facilities: What It Means for Pharma
In September 2025, the U.S. Food and Drug Administration (FDA) released a landmark guidance document titled “Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications.” This guidance redefines how regulators and industry navigate facility assessments for pending drug applications—including NDAs, ANDAs, and BLAs. The new framework signals FDA’s intent to use more flexible, risk-based […]